Tags

Type your tag names separated by a space and hit enter

90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies.
J Mol Endocrinol. 2020 Jul; 65(1):T15-T33.JM

Abstract

Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women's quality of life.

Authors+Show Affiliations

MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh Bioquarter, Edinburgh, UK.MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh Bioquarter, Edinburgh, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32599565

Citation

Critchley, H O D., and R R. Chodankar. "90 YEARS of PROGESTERONE: Selective Progesterone Receptor Modulators in Gynaecological Therapies." Journal of Molecular Endocrinology, vol. 65, no. 1, 2020, pp. T15-T33.
Critchley HOD, Chodankar RR. 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies. J Mol Endocrinol. 2020;65(1):T15-T33.
Critchley, H. O. D., & Chodankar, R. R. (2020). 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies. Journal of Molecular Endocrinology, 65(1), T15-T33. https://doi.org/10.1530/JME-19-0238
Critchley HOD, Chodankar RR. 90 YEARS of PROGESTERONE: Selective Progesterone Receptor Modulators in Gynaecological Therapies. J Mol Endocrinol. 2020;65(1):T15-T33. PubMed PMID: 32599565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies. AU - Critchley,H O D, AU - Chodankar,R R, PY - 2020/01/12/received PY - 2020/01/30/accepted PY - 2020/6/30/entrez PY - 2020/7/1/pubmed PY - 2020/7/1/medline KW - abnormal uterine bleeding (AUB) KW - fibroid KW - heavy menstrual bleeding (HMB) KW - leiomyoma KW - selective progesterone receptor modulators (SPRM) SP - T15 EP - T33 JF - Journal of molecular endocrinology JO - J. Mol. Endocrinol. VL - 65 IS - 1 N2 - Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition affecting one in four women of reproductive age. Current treatments (conservative, medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated pathways, a hormone critical to female reproductive health and disease; therefore, SPRMs hold great potential in fulfilling an unmet need in managing gynaecological disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB in women with leiomyomas and in a higher dose as an emergency contraceptive. In this article, we explore the clinical journey of SPRMs and the need for further interrogation of this class of drugs with the ultimate goal of improving women's quality of life. SN - 1479-6813 UR - https://www.unboundmedicine.com/medline/citation/32599565/90_YEARS_OF_PROGESTERONE:_Selective_progesterone_receptor_modulators_in_gynaecological_therapies L2 - https://jme.bioscientifica.com/doi/10.1530/JME-19-0238 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.